TNFRSF4 and neoplasm: The results showed that PL1-OX40 (ψ) + anti-OX40 Ab enhanced antitumor effects of anti-PD-1 + anti-CTLA-4 Abs immunotherapy, inhibited tumor growth, and extended mouse survival (Supplementary Fig. 20b–e).